The Critical Path Institute has chosen Steven Broadbent as its new chief operating officer. Since early 2009, Broadbent has been the director of consortia operations at the institute. Before joining C-Path, Broadbent was an executive at IBM for nearly 31 years.

Broadbent will take over for Rick Myers, who recently stepped down from the post in order to focus on his role as chairman of the Arizona Board of Regents. Myers will remain a member of C-Path's board of directors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

Nature News writes that researchers are still wrangling over the role of the p-value.

In Nature this week: paternal age associated with de novo mutations in children, and more.